Treatment of Severe Acne Vulgaris — and When Standard Oral or Topical Therapy Has Not Worked
Not all acne responds to first-attempt oral or topical agents. This protocol addresses the specific clinical situation of severe acne vulgaris and cases where standard treatments have not achieved adequate control.
Indicated for patients with severe acne vulgaris, and for those who have failed to respond to standard oral or topical therapy. Both severity and prior treatment failure are recognised entry criteria for this escalated, evidence-based approach.
Treatment Approach
An oral retinoid agent is the recommended intervention in this setting, with specific guidance on formulation selection and dosing strategy covered in the full protocol.
Complete formulation guidance, dosing regimen, and mandatory risk-management requirements are detailed in the full protocol — not shown here.
Treatment Goals
The evidence-supported target is a 90% reduction in lesion count and treatment success at 20 weeks.
References
DOI: 10.1016/j.jaad.2023.12.017
- For patients with severe acne or for patients who have failed standard treatment with oral or topical therapy, we recommend isotretinoin.
- We conditionally recommend daily dosing over intermittent dosing of isotretinoin based on low certainty evidence from 3 RCTs.
- We conditionally recommend either standard isotretinoin or lidose-isotretinoin based on high certainty evidence from 1 study.
- For persons with pregnancy potential, pregnancy prevention is mandatory with isotretinoin treatment.
- In a RCT of 925 patients comparing standard isotretinoin with lidose-isotretinoin, 81.0% of patients treated with standard isotretinoin experienced a 90% reduction in lesion count and 88.9% of patients treated with standard isotretinoin achieved treatment success after 20 weeks of treatment.
View source ↗